The An­ti­dote - Spring 2014

Tak­ing a look at "pharm­er­ging" mar­kets and the re­sur­gence in UK bi­otech IPOs

01/05/2014

We can barely keep up with what is, or is speculated to be, happening in the sector with big pharma. In this edition, we comment on some of the M&A activity and await with interest what may occur over the next weeks and months.

We also look at why the Far East continues to hold so much promise for the sector, particularly in China and Singapore and we look at what may be the start of a resurgence for UK biotech IPOs.

As you may also be aware, CMS today merged with leading Scottish law firm, Dundas & Wilson, and we are delighted to welcome Carina Healy as a member of our core Lifesciences group. Carina brings a wealth of experience to the group and we very much look forward to introducing you to Carina over the coming months.

Publication
The Antidote
Download
PDF 1.3 MB

Authors

Picture of Nick Beckett
Nick Beckett
Managing Partner
Beijing
Sandra Rafferty
Sandra Rafferty
Partner
London
Mr Alex Patience
London
Image of John Markham
John Markham
Senior Associate
London
Picture of Omar Qureshi
Omar Qureshi
Partner
London
Picture of Hanson Sarah
Sarah Hanson
Partner
London
Picture of Gary Green
Gary Green
Partner
London
Picture of Shuna Mason
Shuna Mason
Partner
London
Picture of Carina Healy
Carina Healy
Partner
Glasgow
David Butts
David Butts
Managing Partner
Sofia
Picture of Caroline Hobson
Caroline Hobson
Partner
London
James Parkes
James Parkes
Partner
London
Picture of Sam Dames
Sam Dames
Partner
London - Mayfair
Show more Show less